Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Podar

Showing results (31-40 of 150) with videos related to

Pageof 15
Sort By:
Expert Opinion on Pharmacotherapy|January 21, 2020
Selinexor for the treatment of multiple myelomaKlaus Podar, Jatin Shah, Ajai Chari, et al.
Best Practice & Research. Clinical Haematology|December 12, 2007
The malignant clone and the bone-marrow environmentKlaus Podar, Paul G Richardson, Teru Hideshima, et al.
Expert Opinion on Investigational Drugs|April 10, 2019
Targeting transcription factors in multiple myeloma: evolving therapeutic strategiesShirong Li, Sonia Vallet, Antonio Sacco, et al.
Leukemia & Lymphoma|January 19, 2018
A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myelomaSonia Vallet, Nicholas R Hoyle, Robert A Kyle, et al.
The Journal of Biological Chemistry|January 5, 2002
Dephosphorylation of Ser-259 regulates Raf-1 membrane associationMarkus Kubicek, Margit Pacher, Dietmar Abraham, et al.
Lancet (London, England)|June 23, 2009
Multiple myelomaMarc S Raab, Klaus Podar, Iris Breitkreutz, et al.
Expert Opinion on Pharmacotherapy|July 13, 2022
On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the futureVincent Sunder-Plassmann, Osman Aksoy, Judith Lind, et al.
Cancers|January 21, 2023
Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort StudyStella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, et al.
Cancer Research|October 16, 2003
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cellsDharminder Chauhan, Guilan Li, Reshma Shringarpure, et al.
Expert Opinion on Emerging Drugs|March 3, 2009
Emerging therapies for multiple myelomaKlaus Podar, Yu-Tzu Tai, Teru Hideshima, et al.
Pageof 15

Showing results (31-40 of 150) with videos related to

Sort By:
Pageof 15
Expert Opinion on Pharmacotherapy|January 21, 2020
Selinexor for the treatment of multiple myelomaKlaus Podar, Jatin Shah, Ajai Chari, et al.
Best Practice & Research. Clinical Haematology|December 12, 2007
The malignant clone and the bone-marrow environmentKlaus Podar, Paul G Richardson, Teru Hideshima, et al.
Expert Opinion on Investigational Drugs|April 10, 2019
Targeting transcription factors in multiple myeloma: evolving therapeutic strategiesShirong Li, Sonia Vallet, Antonio Sacco, et al.
Leukemia & Lymphoma|January 19, 2018
A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myelomaSonia Vallet, Nicholas R Hoyle, Robert A Kyle, et al.
The Journal of Biological Chemistry|January 5, 2002
Dephosphorylation of Ser-259 regulates Raf-1 membrane associationMarkus Kubicek, Margit Pacher, Dietmar Abraham, et al.
Lancet (London, England)|June 23, 2009
Multiple myelomaMarc S Raab, Klaus Podar, Iris Breitkreutz, et al.
Expert Opinion on Pharmacotherapy|July 13, 2022
On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the futureVincent Sunder-Plassmann, Osman Aksoy, Judith Lind, et al.
Cancers|January 21, 2023
Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort StudyStella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, et al.
Cancer Research|October 16, 2003
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cellsDharminder Chauhan, Guilan Li, Reshma Shringarpure, et al.
Expert Opinion on Emerging Drugs|March 3, 2009
Emerging therapies for multiple myelomaKlaus Podar, Yu-Tzu Tai, Teru Hideshima, et al.
Pageof 15